Major Depressive Disorder (MDD) Clinical Trials in Orlando, Florida

5 studies are recruiting for major depressive disorder (mdd) in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

   This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Seaport Investigator Site, Orlando, Florida

   Locations

   61 in total

   Run by

   Seaport Therapeutics

   See if you can join NCT07065240 on ClinicalTrials.gov

2. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

   The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Neuroscience Solutions, Inc., Orlando, Florida

   Locations

   26 in total

   Run by

   ACADIA Pharmaceuticals Inc.

   See if you can join NCT07284667 on ClinicalTrials.gov

3. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

   In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo l…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Draig Clinical Site, Orlando, Florida

   Locations

   23 in total

   Run by

   Draig Therapeutics Ltd

   See if you can join NCT07610473 on ClinicalTrials.gov

4. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

   The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Draig Clinical Site, Orlando, Florida

   Locations

   43 in total

   Run by

   Draig Therapeutics Ltd

   See if you can join NCT07300969 on ClinicalTrials.gov

5. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

   The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Clinical Neuroscience Solutions Inc. - Orlando, Orlando, Florida

   Locations

   25 in total

   Run by

   Tonix Pharmaceuticals, Inc.

   See if you can join NCT07621237 on ClinicalTrials.gov